This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.
Full Title of Study: “Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018”
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: May 30, 2019
Arms, Groups and Cohorts
- Paraneoplastic neurological syndromes patients
- Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
Clinical Trial Outcome Measures
- Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018.
- Time Frame: 3 years
- Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.
- Location (city) of diagnosis
- Time Frame: 1 hour
- Name of city where the diagnosis of Paraneoplastic Neurological Syndromes (PNS) or Autoimmune Encephalitis (AE) was made.
- French general population of each counties
- Time Frame: 3 years
- Person years for each region
Participating in This Clinical Trial
- Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018 Exclusion Criteria:
- Data on location of diagnosis missing – Patients diagnosed out of the mainland French territory – Patients for whom insufficient data was available
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Hospices Civils de Lyon
- Provider of Information About this Clinical Study
- Overall Official(s)
- Jérôme Honnorat, Principal Investigator, center for paraneoplastic neurological syndromes and autoimmune encephalitis
- Overall Contact(s)
- Géraldine Picard, 4 72 35 58 42, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.